Press Releases

eyeforpharma recently interviewed: Hans Hoogkamer, Business and Science Affairs, Actelion Pharmaceuticals, Daniel Ghozzi, Managing Director CIS, UCB Pharma Russia & Rune Pilegaard  Associate Director, Business Support Nordics Sanofi-Aventis to see what they will be focusing on for the next...

Shire plc, the global specialty biopharmaceutical company, today announced results from a study of Vyvanse®, assessing its effect in a model for Excessive Daytime Sleepiness (EDS).  Vyvanse is a prescription medicine currently approved in the US, Canada and Brazil...

Merck KGaA announced that recruitment has been completed for the pivotal Phase III EXPAND(a) clinical trial investigating the efficacy of Erbitux® (cetuximab) in treating patients with advanced gastric cancer. The international study has recruited more than 870 patients since...

Bristol-Myers Squibb Company and AstraZeneca announced that KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States. ...

NovaBay Pharmaceuticals, a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay’s lead Aganocide, NVC-422 has shown in vitro activity against the...

H. Lundbeck A/S (Lundbeck) announced the completion of two out of three pivotal studies in the phase III clinical programme for nalmefene in alcohol dependence (ESENSE1 and SENSE). The studies were conducted in Europe and enrolled about 1,300 patients...

Innovate in an era of cost-effectiveness: Realise the value of personalised medicine Discover how to strengthen your drug pipeline with companion diagnostics How to access the market Hear about the expectation of the pharmaceutical and diagnostics industry and...